University of Portsmouth, School of Health Sciences & Social Work, James Watson Hall (West), 2 King Richard 1st Road, PortsmouthUK, PO1 2FR Show
Southampton University Hospitals NHS Trust, Royal South Hants Hospital, Cancer Care Directorate, St Mary's Road, SouthamptonHampshireUK University of Portsmouth, Department of Mathematics, Lion Gate Building, Lion Terrace, Portsmouth, HampshireUK, PO1 3HF Mountbatten Hospice, Isle of Wight NHS Trust, Halbery Lane, NewportIsle of WightUK AbstractBackgroundCancer cachexia is a distressing weight loss syndrome commonly seen in advanced cancer patients. It is associated with reduced quality of life and shorter survival time. Eicosapentaenoic acid (EPA) is a long chain polyunsaturated fatty acid found naturally in some fish which has been used to decrease weight loss, promote weight gain and increase survival times in patients affected with cancer cachexia. ObjectivesTo evaluate the effectiveness and safety of EPA in relieving symptoms associated with the cachexia syndrome in patients with advanced cancer. Search methodsStudies were sought through an extensive search of a range of electronic databases. Hand searching was conducted on selected journals and reference lists as well as contact made with investigators, manufacturers and experts. The most recent electronic search was conducted in February 2005. Selection criteriaStudies were included in the review if they assessed oral EPA compared with placebo or control in randomised controlled trials of patients with advanced cancer and either a clinical diagnosis of cachexia or self‐reported weight loss of 5% or more. Data collection and analysisBoth methodological quality evaluation of potential trials and data extraction were conducted by two independent review authors. Main resultsFive trials (involving 587 participants) met the inclusion criteria. Three trials compared EPA at different doses with placebo with two outcomes, nutritional status and adverse events comparable across two of the three included trials. In addition, two trials compared different doses of EPA with an active matched control. It was possible to compare the outcomes of weight, quality of life and adverse events across these two trials. There were insufficient data to define the optimal dose of EPA. Authors' conclusionsThere were insufficient data to establish whether oral EPA was better than placebo. Comparisons of EPA combined with a protein energy supplementation versus a protein energy supplementation (without EPA) in the presence of an appetite stimulant (Megestrol Acetate) provided no evidence that EPA improves symptoms associated with the cachexia syndrome often seen in patients with advanced cancer. Plain language summaryUsing an omega‐3 fatty acid made from fish oils to treat cancer related weight loss There was insufficient evidence to support the use of oral fish oil (on its own or in the presence of other treatments) for the management of the weight loss syndrome often seen in patients with advanced cancer. Many people with advanced cancer develop a distressing weight loss syndrome. To date, treatment of associated symptoms has proved difficult. More recently, novel approaches have included the use of oral fish oils that can contain the omega‐3 fatty acid eicosapentaenoic acid (or EPA) to stabilise weight loss and promote weight gain. This review of trials found that in weight losing persons with advanced pancreatic cancer, an EPA nutritional supplement was no better than a non EPA nutritional supplement. However, there was insufficient evidence to draw conclusions about its use in patients who have cancer of other tumour types. BackgroundCancer cachexia is a debilitating weight loss syndrome characterised by disease‐induced starvation and wasting (). Whilst there is no universally accepted definition of cachexia, the clinical signs that form the hallmark of cancer associated cachexia are anorexia and extreme weight loss. Although a 10% weight loss (from pre‐illness weight) is often considered to be severe, the rate of the weight loss can also be of primary importance in the definition of cachexia. Categories of severe weight loss have been defined as more than 2% in one week, 5% in one month and 10% in six months (). Other clinical features include abnormalities in carbohydrate, fat, protein and energy metabolism which lead to weakness, lethargy, malaise and the loss of skeletal muscle and adipose tissue (). Patients have a "starved" or "cachetic" appearance and are often described as "looking ill" (). Cachexia is seen in approximately half of all terminally ill cancer patients and is particularly associated with solid cancer tumours of the stomach, lung and pancreas. The literature suggests that cachexia rates for these particular cancers can be more than 80% in pancreatic and gastric cancer (). Cachectic patients have shorter survival time when compared to other terminally ill cancer patients without extreme weight loss (). Such severe weight loss has also been associated with reduced quality of life, impaired respiratory muscle function, fatigue and poor self‐image have all been cited (). Profound muscle weakness may lead to loss of physical function and deterioration of performance status. Associated fatigue and weakness may impair a patient's ability to perform even simple activities of daily life such as dressing, preparing and eating meals. In addition physical fatigue coupled with dramatic weight loss can give rise to a change in body image which, in turn, can lead to the patient perceiving that they are progressively looking more ill and may contribute to depression and decreased social interactions (). The exact cause of cachexia is unknown, but it is likely to be multi‐fold and can be grouped into three interrelated categories to include:
Specific proteolysis and lipolysis tumour products have been identified (; ; ) but comparative studies of these factors which have been isolated have yet to be reported. Past attempts to improve the patient's nutritional status using conventional oral nutritional supplements or parenteral nutrition have proved unsuccessful (; ). Although reduced appetite is often associated with cachexia, increasing calorific intake has not been shown to alter its progression. Corticosteroids, including prednisolone have been used successfully to temporarily increase the patient's appetite, but this has not improved nutritional status (). More recently, novel approaches have included the use of fish oils which may have an anti‐cachectic effect after a period of three weeks or more to produce significant weight gain, performance status and increased appetite in patients with cancer cachexia (). Fish oils contain the long chain polyunsaturated fatty acids, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). In animal studies, using mice, EPA was found to stabilise weight loss in tumour induced cachexia. A similar anticachectic effect was not reproduced by the use of DHA alone (). The biological rationale for using EPA is that it has been shown to inhibit tumour induced lipolysis and muscle protein degradation, probably by the suppression of the cytokine IL‐6 and by decreasing the presence of a tumour specific product, a proteolysis‐inducing factor (or PIF) (). EPA is found naturally in some seafood, including salmon, sardines and tuna. In its manufactured form, EPA is available in fish oil preparations over‐the‐counter, without prescription, in both a soft gelatin capsule or liquid form. Outside of clinical trials, commercially available over‐the‐counter products may vary in EPA concentration and quality since, to date, it is not compulsary for manufacturers to accurately record the EPA content on product labels. Generally, its use has raised few concerns regarding side effects and has been shown to be non‐toxic, well tolerated and free of significant side effects in all but high dosage trials. In patients with pancreatic cancer the dosage tolerated was limited by a sensation of fullness, cramping abdominal pain, fatty stools and nausea (). Evidence from non‐randomised trials, trials without a control group and randomised controlled trials suggest that there is some therapeutic use of EPA taken for at least a four week period to reverse cancer cachexia by decreasing weight loss or improving weight gain, or both, to increase survival time in patients with cancer cachexia (; ; ). Many of these trials have been small, using variable dosage rates and inadequate study design which may have over emphasised evidence of effect. Since the best evidence of effectiveness of health interventions comes from results of well‐conducted randomised controlled trials, a systematic review of quality assessed randomised controlled trials, with a meta‐analysis, may help to synthesise such data. ObjectivesThe objective of this review was to determine the effectiveness and safety of the omega‐3 fatty acid eicosapentaenoic acid (EPA) to alleviate cachexia and related symptoms in patients with incurable or advanced cancer. MethodsCriteria for considering studies for this reviewTypes of studiesRandomised controlled trials (RCTs) that were double blind, single blind or unblinded were included providing they met the methodological quality assessment process. Both inpatient and outpatient study settings were included. It was anticipated that we would include only trials with a minimum of three weeks after randomisation into the study in order that any meaningful weight change would be recorded. However, it was decided that instead, as there were few studies that met the methodological quality assessment threshold, all well conducted studies, including those of short duration, would be included. Types of participantsTrials of patients with a confirmed diagnosis of incurable or advanced cancer and either a reported weight loss of 5% and above or a clinical diagnosis of cachexia (independent of gender, age or race) were included. Types of interventionsThis review focuses on the following treatment comparisons:
Types of outcome measuresPrimary outcomesThe primary outcome measures assessed were:
Secondary outcomesThe secondary outcome measures assessed were:
Search methods for identification of studiesElectronic searchesA search strategy (using both free text and MeSH terms and without methodological terms as filters) was designed for identifying studies from the following databases:
As recommended by the Cochrane Handbook, searching was carried out without using filters in order to maximise retrieval of as many studies as possible. Study reports were retrieved regardless of whether these were full publications, abstracts or letters to the editor. The search strategy was adapted as necessary to search different databases using the relevant Boolean and truncation terms for each database, as required. Please see for the MEDLINE search strategy. Studies were not excluded on the basis of language or publication status (published, unpublished, in press and in progress). Full text translations of all relevant non‐English articles were obtained. Searching electronic databases identified:
Searching other resourcesHand searchingThe following journals were identified as being important to be hand searched for this review and searched as follows:
Hand searching of secondary references revealed 50 potential articles. Contact with experts revealed 16 potential trials, and manufacturer's information revealed six potential trials. Hand searching of conference proceedings revealed a further four potential trials. Hand searching of specified, relevant journals revealed no new potential trials. Personal contact
Data collection and analysisStudy selectionFrom the title, abstract or descriptors, one review author (AD) reviewed the literature searches to identify potentially relevant trials for the review. Searches of bibliographies and texts were conducted to identify additional studies. Trials to be included were determined independently by two review authors (AD and BH) and assessed for inclusion in the review. Duplicate trials using the same participants but different outcomes were included only once. Study qualityTwo review authors (AD and BH and where necessary TD) independently carried out quality assessment as follows:
Data extractionUsing a specially designed data extraction form, two review authors (AD and BH) extracted data on patients, methods, interventions, outcomes and results. Differences in data extraction were resolved by initial referral back to the original article, followed by discussion and consensus between the two review authors (AD and BH). Where necessary, missing information or clarification was sought from the authors of the primary study. Correspondence with authorsThree of the included studies either did not report all of the desired outcomes of interest or presented them in a format unsuitable for inclusion in the meta‐analysis. An e‐mail or letter requesting missing information was sent. Data analysisWhere appropriate outcome data was entered using Cochrane Review Manager software (version 4.2) for statistical analysis to obtain an estimate of treatment effect. Tests for heterogeneity were also performed on the data. Dichotomous data was expressed as the odds ratio (OR) and results presented with 95% confidence intervals using a fixed‐effect analysis. Continuous outcomes were compared using weighted mean differences in a fixed effects analysis. There were an insufficient number of trials to conduct any meaningful sensitivity analysis. The type of analysis for each trial was recorded as follows:
ResultsDescription of studiesAlthough, 759 articles were located, we found many of the citations were replicated across the three databases or referred to review articles. We located 59 potential trials for inclusion in the review. However, many of these studies did not fully meet the inclusion criteria or quality assessment threshold. Reasons for rejecting individual studies are detailed in the 'Characteristics of Excluded Studies' table. In addition we located one unpublished trial () led by the chief investigator, Professor KC Fearon from the Department of Clinical and Surgical Sciences at the Royal Infirmary of Edinburgh, UK. This trial is currently undergoing peer review prior to publication. It is hoped that at the review date of this systematic review we will be able to include the data from this trial (see '' table) (). A total of five trials fully met the inclusion criteria for this review and provided data for analysis (; ; ; ; ). Effects of interventionsThe five trials meeting the inclusion criteria involved a total of 587 patients. Three trials compared EPA at different doses with placebo (; and ). Two trials (; ) compared different doses of EPA versus matched active control (but without EPA). Patient characteristicsrandomised 91 patients (46 to fish oil and 45 to placebo) with the following characteristics: advanced cancer (defined by locally recurrent or metastatic disease) more than 5% pre‐illness weight loss (time period of weight loss not specified), presence of anorexia but the ability to maintain oral food intake over the two‐week study period) as well as normal cognitive status. Cancer types included: genitourinary, breast, gastrointestinal, lung, hematologic, head and neck and sarcoma tumours. At baseline, there was no significant difference between arms. randomised 64 patients with generalised solid tumour of the following cancer types: breast, gastrointestinal, lung, liver and pancreas. Each arm was then sub‐divided into the following two subgroups, those considered to be in a good nutritional state or well nourished (WN) and malnourished (MN). Patients in the well‐nourished (WN) subgroups in both arms included patients who had a less than 10% weight loss over the previous six months, serum albumin of more than 30 g/L, serum transferrin of more than 2.0 g/L and a Karnofsky Performance status of more than 60. Patients in the malnourished (MN) subgroups of both arms included patients that had a weight loss of more than 10% during the previous six months, serum albumin of less than 30 g/L, serum transferrin of less than 2.0 g/L and Karnofsky Performance status of less than 60. In addition a group of 15 healthy individuals served as controls. randomised 17 patients with different cancer tumour types including: gastrointestinal tract, pancreatic, rectal, renal, breast, oesophageal, lung, mesothelioma, cervical, carcinoid and adenocarcinoma of unknown primary site. All but one patient in the fish oil arm had metastatic disease or locoregional relapse, or both. Weight loss ranged from 5.3% to 18.1% in the preceding six months. Baseline characteristics appear to be similar although despite randomisation, energy intake at baseline was significantly higher in the EPA arm compared to the placebo arm. Sixteen healthy subjects acted as controls. randomised 200 unresectable pancreatic cancer patients who had lost more than 5% of pre‐illness weight over the previous six months. The trial was included with patients having a Karnofsky performance score of 60 or more and a life expectancy of greater than two months. The average pre‐illness weight loss was 17%. At baseline there was no significant difference between the treatment arms in terms of sex, performance status and quality of life characteristics. In the EPA arm there was a greater proportion of stage IV disease patients (52%) than in the placebo arm (41%). randomised 421 patients with incurable cancer; lung, gastrointestinal and others. All patients had associated weight loss defined as a self‐reported two‐month weight loss of at least 2.3 kgs or physician estimated calorific intake of less than 20 calories/kg of body weight/day, or both. At baseline, there was no significant difference found between the three treatment arms of patient groups in terms of Eastern Cooperative oncology group performance status, Karnofsky score physician estimate of survival, patient reported appetite or medical centre of enrolment. In addition, there were no significant difference on the basis of stratification factors:
In summary the five trials that met the inclusion criteria involved a total of 587 patients. The mean age of patients included in the treatment arms across all trials was 66.4 years compared to a mean age of 65.6 in the control arms. The ratio of males to females in the treatment arms was 172M/117F compared to 174M/124F in the control arms. In terms of study size the trial was the smallest (n = 17) with trial recruiting the largest number of patients (n = 421). The majority of trials included patients with a variety of tumours. Only the trial was limited to patients with pancreatic cancer. Use of steroidsOnly one study () excluded patients taking any dosage of corticosteroids. Three studies stated that patients were included if taking corticosteroids, but in the study only short term dexamethasone (dose unstated) with chemotherapy was permitted and in study patients taking long term low dose steroids for chronic benign conditions (such as asthma) and not for physiological replacement were included. In the study patients continued with corticosteroids for the two‐weeks trial (n = 8) but no details of dosage were provided. In the study there is no mention of steroids being included or excluded and despite repeated efforts to contact the authors we were unsuccessful in gaining information for clarification. Adjunct chemotherapy and/radiotherapyThree studies stated that they excluded patients who were undergoing current chemotherapy (; ; ). The study allowed chemotherapy (n = 5) and antineoplastic hormone therapy (n = 4) and the study allowed concurrent chemotherapy and radiotherapy. InterventionsComparison one ‐ EPA versus placeboThree trials (; and ) compared EPA at different doses with placebo as follows: In the trial, 60 patients with mixed cancer tumour types were randomised to receive 18 gelatin capsules of 1000 mgs of fish oil (each containing: 180 mg EPA, 120 DHA (docosahexaenoic acid) with the addition of 1 mg of Vitamin E); or 1000 mgs of a placebo capsule (olive oil). After random assignment of 19 patients (nine fish oil and ten placebo) high level of complaints of vomiting in approximately ten patients (in both arms) suggested that these patients were unable to tolerate 18 capsules/day. The trial protocol was amended to six capsules/day with encouragement to take up to 18 capsules/day. The trial lasted two weeks with assessments (subjective and objective measurements) performed at baseline and on day 14.
Comparison two ‐ EPA versus matched active treatment controlTwo trials ( and ) compared different doses of EPA versus matched active control.
The median number of days on the study was slightly more than three months for the arms as a whole. All patients were assessed weekly for four weeks and then monthly with patients continuing treatment as long as both the patient and treating oncologist considered it beneficial, or acceptable, to the patient. ComplianceTwo trials reported details on compliance. In the trial, patients in the EPA arm took a mean (SD) of 9.8 +/‐ 4 capsules per day compared to those in the placebo arm who took a mean (SD) of 9.2 +/‐ 3 capsules (P = not significant). In the EPA arm this resulted in patients consuming an average of 1.8 g EPA/day. In the trial, patients in both arms consumed an average of 1.4 cans (equivalent to 40 kcal, 21 g protein/day). In the EPA arm this resulted in patients consuming an average of 1.5 g EPA/day. No details were given for compliance for three trials (; ; ). Withdrawals and dropoutsAll five trials reported the total number of dropouts and withdrawals but the trial failed to give specific details for each arm of the trial. reported four withdrawals due to poor compliance, but details of which arm patients belonged to were not recorded. For four trials (; ; and ) total numbers of patient withdrawal and dropout was 64 in the EPA arms and 62 in the control arms. None of the trials reported that withdrawals were due to lack of efficacy of treatment (see 'Additional Tables', Table one, for individual trial details of withdrawals and dropouts). ToleranceThe patient's ability to tolerate the supplements was measured in relation to side effects and adverse events. These included gastrointestinal symptoms (e.g. mild abdominal discomfort, transient diarrhoea, nausea and vomiting) particularly in the higher dosage trials. In addition, there was a higher incidence of impotence in the study in those patients receiving MA, although such patient‐reported symptoms were not assessed at baseline. Only one of the trials () found there were significantly fewer adverse events in the EPA arm compared with the active control arm. The other four trials showed a tendency towards fewer adverse events in the EPA arm, but the differences were not significant. Combining data on adverse events from Comparison one (EPA versus placebo) and Comparison two (EPA versus active treatment control group) in a meta‐analysis of all the trials supported 's findings that there were significantly fewer adverse events. A plausible explanation of this finding is that these adverse events were due to the patient's deteriorating condition and not the action of EPA, placebo or active control. ResultsAs this review focuses on specific outcomes measured using validated tools, the results reflect these criteria. Whilst some trials also reported results (such as immune status) these have not been incorporated in the present work. Comparison two ‐ EPA versus matched active treatment controlTwo trials looked at EPA versus matched active treatment control. For each of these included studies the control used a matched active treatment as follows:
For the purpose of this systematic review, however, we have selected two of the three comparisons (Arm two and Arm three) so that the only difference between these two arms of the study was the addition of EPA. In this way, we were able to compare some of the relevant outcome measures, namely: weight, Quality of Life and adverse events. Although planned meta‐analysis of data for both comparisons were not conducted for the majority of reported outcomes due to the lack of common measures, a narrative summary provides an indication of the likely benefits and harms of the remaining outcomes of interest. Primary outcomes1. Weight gainComparison one ‐ EPA versus placeboOnly one of the three included studies, (Assessment based on 60 patients) reported weight gain. In this trial, although there was a slight increase in weight gain for patients in the EPA arm the results were not significant. Comparison two ‐ EPA versus matched active treatment control
2. Body compositionBody composition refers to assessment of subcutaneous fat and muscle tissue and can be more useful to assess the patient's nutritional status than gross body weight which may be complicated by fluid retention if patients develop oedema or ascites. The use of techniques such as bioelectrical impedance analysis or anthropometry can provide a more accurate description of the nature of tissue loss. Bioelectrical impedance analysis is a non‐invasive method of determining body composition based on the measurement of reactance and resistance to electrical flow (). The most commonly used anthropometric measures are triceps skin fold thickness (or TSF) and mid‐upper arm circumference (or MAC) which are combined to provide an indirect determinate of mid‐arm muscle area (or MAMA). Other more specialised techniques such as dual‐energy X‐ray absorption and computer tomography can be used although both techniques involve high capital investment and may not be suitable for use in the clinical setting (). Comparison one ‐ EPA versus placeboOf the three included studies, only one study () reported body composition. Using anthropometry, lean body mass was estimated using anthropometric measurements carried out on days one and 14, but were not statistically significant difference for patients in the EPA treatment arm compared with those in the placebo arm. Comparison two ‐ EPA versus matched active treatment controlOf the two included studies, only the study measured lean body mass which was measured using bioelectrical impedance analysis. When compared to rate of loss at baseline there was a significant attenuation of lean body mass in both of the study arms (EPA and Control) at four and eight weeks (P < 0.001 for all within group comparisons). However, there was no significant difference between groups (P = 0.88). Again, although not the primary outcome of the study, conducted post‐hoc analysis to examine for a potential dose‐response relationship in either arm (EPA or Control). This post‐hoc analysis showed a significant positive increase in the EPA arm between daily supplement intake and increase in lean body mass (r = 0.33, P = 0.036). The correlation between intake and lean body mass gain was significantly greater in the EPA arm than in the control arm (P = 0.0043). 3. SurvivalComparison one ‐ EPA versus placeboOf the three included studies, only the provided survival data. Actual numbers for survival days were not provided and we were unable to confirm these figures. Survival days have been estimated from the published diagram. This data suggests that all patients in the EPA arm (n = 30) had a statistically significant (P = < 0.025) increase in survival compared with the placebo arm. In the EPA arm, well‐nourished (WN) patients survived 870 days and malnourished (MN) patients survived 600 days compared to all patients (n = 30) in the placebo arm (WN = 480 days, MN = 242 days). In addition, best survival was noted for the group of WN patients in the EPA arm compared to the MN patients in the placebo arm (870 days compared to MN = 242 days). Comparison two ‐ EPA versus matched active treatment controlAlthough both included studies (; ) reported some data on survival there were insufficient data available to combine in a meta‐analysis.
Secondary Outcomes4. Quality of lifeComparison one ‐ EPA versus placebo
Comparison two ‐ EPA versus matched active treatment control
5. Energy expenditureNone of the included studies for either comparisons measured energy expenditure. 6. Reduction in fatigueComparison one ‐ EPA versus placebo
Comparison two ‐ EPA versus active treatment control
7. Functional or performance statusFunctional or performance status refers to the patient's ability to function independently and includes the patient's ability to work and to be active. There are a number of validated, quick and simple to use performance tools (such as the Karnofsky Performance Scale and the World Health Organisation Scale) which have been used with cancer patients. Comparison one ‐ EPA versus placebo
Comparison two ‐ EPA versus matched active treatment control
8. Nutritional statusA variety of subjective and objective methods may be used to assess nutritional status. As well as gross weight and lean body mass which have already been included in the systematic review as separate outcomes, other measurements of nutritional status may include administration of nutritional assessment questionnaires as well as assessment of dietary intake and changes in laboratory values related to nutritional status. Only data on dietary intake was available from three of the included studies as follows. Comparison one ‐ EPA versus placeboTwo studies (; ) measured total energy intake as calorific intake per day () and kilo joules/day ().
Comparison two ‐ EPA versus matched active treatment controlOf the two included studies, one study () assessed nutritional status by measuring total calorific and protein intake per day. At baseline, patients in both arms of the study were consuming insufficient intakes of energy and protein to maintain body weight. Although spontaneous intake was partially reduced, when patients in both the EPA Control arm consumed an average 1.4 cans of oral supplement (equivalent to 420 kcal and 21 g protein/day) oral supplementation in both arms provided a net gain in total energy and protein intake. 9. Appetite statusComparison one ‐ EPA versus placeboOnly the () study measured appetite status which was measured using a VAS (zero to 100 mm where 0 mm = best and 100 mm = worse) and negative numbers denote improvement in VAS. Although there was a trend for appetite improvement in both arms (Treatment Arm: ‐9.8+/‐20, Placebo Arm: ‐9.0+/‐27) there was no significant improvement in appetite in either arm. Comparison two ‐ EPA versus matched active treatment controlOnly the study measured appetite status using the NCCTG questionnaire which provided useful data to describe the percentage of patients that reported varying levels of improvement above baseline intake. There was no significant difference between the two arms. DiscussionThe aim of this review was to assess the effectiveness of EPA for the management of the distressing weight loss syndrome, cachexia, often seen in patients with advanced cancer. Despite a thorough search for evidence, too few well‐conducted studies with common outcomes of interest were available to conduct a meta‐analysis which has made it difficult to draw conclusions. At present, therefore, limited evidence does not support the use of fish oils containing EPA either on its own or in the presence of other treatments. Comparison one ‐ EPA versus placeboThree small studies (; ; ) met the methodological inclusion criteria and reported results on a total 150 patients with mixed cancer tumours and weight loss. Apart from adverse events, it was frustrating that there was only one common outcome measure, nutritional status, that could be compared across two of these three studies. There were, therefore, insufficient data to determine whether oral EPA was better than placebo for the patient identified outcomes of interest to this systematic review.
Comparison two ‐ EPA versus matched active treatment controlTwo large high quality multi‐centered studies were identified (; ). In the study they compared a protein energy supplementation (with or without EPA). Whilst for the study we took the data from two of the three arms (the appetite stimulant, Megestrol acetate combined with an EPA protein supplementation versus Megestrol acetate appetite stimulant and protein supplementation without EPA). In this way the only difference between the two arms was the addition of EPA.
Authors' conclusionsImplications for practiceThe conduct of this systematic review did not enable us to confirm or refute previous literature on the use of EPA and it was not possible to recommend its use in clinical practice. Whilst the results from this systematic review suggests that there is little evidence of harm from using EPA it may not be reasonable to suggest its use in people who are very ill or if palatability is low and problems of compliance occur. There appears to be no significant improvement in management of symptoms by the addition of EPA to that gained from patients taking a high calorie, high protein nutritional supplement with or without the addition of the appetite stimulant, Megestrol Acetate (MA). Indeed it may be that combining EPA with MA may have a slight inhibitory action on MA. Implications for researchThe conduct of this systematic review has revealed a paucity of well‐conducted randomised controlled trials to adequately answer the review questions posed. Furthermore many of the trials were poorly reported which made it difficult and time‐consuming to assess their suitability. However, we found improved reporting in those trials which appear to have been designed and reported in accordance with the Consolidated Standards of Reporting Trials statement (CONSORT Statement) which includes a 22‐item checklist and a flow diagram and its use should be encouraged (). There is a need to conduct good quality large scale randomised controlled trials using EPA compared to placebo with different cancer types. In particular, the potential survival advantage of the addition of EPA needs to be explored. We also found that many of the included trials permitted concurrent use of other supportive therapies such as corticosteroids (four of the five trials) palliative chemotherapy (one trial) and radiotherapy (two trials) which may have masked the true benefit of the addition of EPA alone. Future trials could exclude other supportive therapies or incorporate appropriate stratification. In addition, it may be necessary for future studies to consider using a more palatable formulation of EPA. Finally, we found a paucity of studies that recruit patients at an early stage in their disease progression. Recruiting patients in to the study with minimal weight loss and at an earlier stage may provide a better opportunity to encourage compliance and provide enough time to assess meaningful improvements. The challenges will be identifying and recruiting suitable cancer patients into such a study. What's newHistoryProtocol first published: Issue 1, 2004 Review first published: Issue 1, 2007 DateEventDescription25 January 2017AmendedSee .9 April 2015AmendedThis review has been identified as a priority for updating, but additional authors are required. See .19 April 2012AmendedAdditional tables not linked within the text were deleted from this version of the review and the Risk of bias tables were updated.24 September 2010AmendedContact details updated.27 October 2008AmendedFurther RM5 changes1 July 2008AmendedConverted to new review format. NotesThe updated review is planned for publication in 2016. The lead author requires additional systematic reviewers to join the author team in order to complete this important update. Please contact the lead author or the PaPaS team ([email protected]) directly if you would like to apply to support the development of this update. At January 2017, the author team has been established and the update is being prepared. At December 2017, this is no longer being updated, the author team does not have the time or resources to complete this update. Acknowledgements
AppendicesAppendix 1. MEDLINE search strategyNote: Controlled vocabulary (Mesh terms) are presented in uppercase, free text terms are presented in lowercase text 1. CACHEXIA 2. cachexia 3. cachectic OR cachexic 4. disease‐induced adj starvation 5. wasting 6. (weight adj loss) OR (weight adj3 gain$) 7. (weight adj3 lost) OR (weight adj3 lose) OR (weight adj3 losing) 8. WEIGHT LOSS 9. ANOREXIA 10. anorex$ 11. OR/1‐10 12. exp FISH OILS 13. 58111417‐EICOSAPENTAENOIC ACID 14. DOCOSAHEXAENOIC ACIDS 15. FATTY ACIDS OMEGA‐3 16. FATTY ACIDS UNSATURATED 17. Fatty acid$ 18. EFA.ti.ab 19. MaxEPA.ti.ab 20. (oil$ adj6 cod$) 21. (oil$ adj6 marin$) 22. (oil$ ad6 fish$) 23. omega3$ 24. omega‐3$ 25. EPA OR DHA.ti.ab 26. (eicosapentaen$ OR icosapentaenoic) OR docosahexaeno$) 27. OR/12‐26 28. Exp NEOPLASMS 29. neoplasm$ OR cancer$ OR carcino$ OR malignan$ OR tumor$ OR tumour*) 30. 28 OR 29 31. 11 AND 27 AND 30 The search strategy was organised into three distinct groups as follows: Group 1 Terms for cachexia (lines 1 to 11) Group 2 Terms for fish oils (lines 12 to 27) Group 3 Terms for cancer (lines 28 to 30) NotesEdited (no change to conclusions) Data and analysesComparison 1Oral EPA at any dose versus placebo Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Differences in weight1 Mean Difference (IV, Fixed, 95% CI)Totals not selected2 Differences in lean body mass1 Mean Difference (IV, Fixed, 95% CI)Totals not selected3 Resting Energy expenditure1 Mean Difference (IV, Fixed, 95% CI)Totals not selected4 Any Adverse Events277Odds Ratio (M‐H, Fixed, 95% CI)0.78 [0.31, 1.95]5 Appetite status1 Mean Difference (IV, Fixed, 95% CI)Totals not selected6 Fatigue1 Mean Difference (IV, Fixed, 95% CI)Totals not selected7 Performance status ‐ karnofsky score1 Mean Difference (IV, Fixed, 95% CI)Totals not selected8 Performance scales = Edmonton Functonal Assessment Test1 Mean Difference (IV, Fixed, 95% CI)Totals not selected9 Total Calorific intake277Std. Mean Difference (IV, Fixed, 95% CI)0.20 [‐0.25, 0.65]10 Nausea1 Mean Difference (IV, Fixed, 95% CI)Totals not selected11 Wellbeing1 Mean Difference (IV, Fixed, 95% CI)Totals not selected ![An external file that holds a picture, illustration, etc. Object name is nCD004597-CMP-001-01.jpg](https://https://i0.wp.com/www.ncbi.nlm.nih.gov/pmc/articles/PMC6464930/bin/nCD004597-CMP-001-01.jpg) Analysis Comparison 1 Oral EPA at any dose versus placebo, Outcome 1 Differences in weight. ![An external file that holds a picture, illustration, etc. Object name is nCD004597-CMP-001-02.jpg](https://https://i0.wp.com/www.ncbi.nlm.nih.gov/pmc/articles/PMC6464930/bin/nCD004597-CMP-001-02.jpg) Analysis Comparison 1 Oral EPA at any dose versus placebo, Outcome 2 Differences in lean body mass. ![An external file that holds a picture, illustration, etc. Object name is nCD004597-CMP-001-03.jpg](https://https://i0.wp.com/www.ncbi.nlm.nih.gov/pmc/articles/PMC6464930/bin/nCD004597-CMP-001-03.jpg) Analysis Comparison 1 Oral EPA at any dose versus placebo, Outcome 3 Resting Energy expenditure. ![An external file that holds a picture, illustration, etc. Object name is nCD004597-CMP-001-04.jpg](https://https://i0.wp.com/www.ncbi.nlm.nih.gov/pmc/articles/PMC6464930/bin/nCD004597-CMP-001-04.jpg) Analysis Comparison 1 Oral EPA at any dose versus placebo, Outcome 4 Any Adverse Events. ![An external file that holds a picture, illustration, etc. Object name is nCD004597-CMP-001-05.jpg](https://https://i0.wp.com/www.ncbi.nlm.nih.gov/pmc/articles/PMC6464930/bin/nCD004597-CMP-001-05.jpg) Analysis Comparison 1 Oral EPA at any dose versus placebo, Outcome 5 Appetite status. ![An external file that holds a picture, illustration, etc. Object name is nCD004597-CMP-001-06.jpg](https://https://i0.wp.com/www.ncbi.nlm.nih.gov/pmc/articles/PMC6464930/bin/nCD004597-CMP-001-06.jpg) Analysis Comparison 1 Oral EPA at any dose versus placebo, Outcome 6 Fatigue. ![An external file that holds a picture, illustration, etc. Object name is nCD004597-CMP-001-07.jpg](https://https://i0.wp.com/www.ncbi.nlm.nih.gov/pmc/articles/PMC6464930/bin/nCD004597-CMP-001-07.jpg) Analysis Comparison 1 Oral EPA at any dose versus placebo, Outcome 7 Performance status ‐ karnofsky score. ![An external file that holds a picture, illustration, etc. Object name is nCD004597-CMP-001-08.jpg](https://https://i0.wp.com/www.ncbi.nlm.nih.gov/pmc/articles/PMC6464930/bin/nCD004597-CMP-001-08.jpg) Analysis Comparison 1 Oral EPA at any dose versus placebo, Outcome 8 Performance scales = Edmonton Functonal Assessment Test. ![An external file that holds a picture, illustration, etc. Object name is nCD004597-CMP-001-09.jpg](https://https://i0.wp.com/www.ncbi.nlm.nih.gov/pmc/articles/PMC6464930/bin/nCD004597-CMP-001-09.jpg) Analysis Comparison 1 Oral EPA at any dose versus placebo, Outcome 9 Total Calorific intake. ![An external file that holds a picture, illustration, etc. Object name is nCD004597-CMP-001-10.jpg](https://https://i0.wp.com/www.ncbi.nlm.nih.gov/pmc/articles/PMC6464930/bin/nCD004597-CMP-001-10.jpg) Analysis Comparison 1 Oral EPA at any dose versus placebo, Outcome 10 Nausea. ![An external file that holds a picture, illustration, etc. Object name is nCD004597-CMP-001-11.jpg](https://https://i0.wp.com/www.ncbi.nlm.nih.gov/pmc/articles/PMC6464930/bin/nCD004597-CMP-001-11.jpg) Analysis Comparison 1 Oral EPA at any dose versus placebo, Outcome 11 Wellbeing. Comparison 2Oral EPA versus control Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Weight or weight change2390Mean Difference (IV, Fixed, 95% CI)‐0.15 [‐0.78, 0.47]2 lean body mass or change in LBM1 Mean Difference (IV, Fixed, 95% CI)Totals not selected3 Any Adverse Events2456Odds Ratio (M‐H, Fixed, 95% CI)0.48 [0.25, 0.91]4 Performance status1 Mean Difference (IV, Fixed, 95% CI)Totals not selected5 Quality of Life2384Mean Difference (IV, Fixed, 95% CI)‐1.70 [‐6.11, 2.70]6 Total Calorific intake1 Std. Mean Difference (IV, Fixed, 95% CI)Totals not selected ![An external file that holds a picture, illustration, etc. Object name is nCD004597-CMP-002-01.jpg](https://https://i0.wp.com/www.ncbi.nlm.nih.gov/pmc/articles/PMC6464930/bin/nCD004597-CMP-002-01.jpg) Analysis Comparison 2 Oral EPA versus control, Outcome 1 Weight or weight change. ![An external file that holds a picture, illustration, etc. Object name is nCD004597-CMP-002-02.jpg](https://https://i0.wp.com/www.ncbi.nlm.nih.gov/pmc/articles/PMC6464930/bin/nCD004597-CMP-002-02.jpg) Analysis Comparison 2 Oral EPA versus control, Outcome 2 lean body mass or change in LBM. ![An external file that holds a picture, illustration, etc. Object name is nCD004597-CMP-002-03.jpg](https://https://i0.wp.com/www.ncbi.nlm.nih.gov/pmc/articles/PMC6464930/bin/nCD004597-CMP-002-03.jpg) Analysis Comparison 2 Oral EPA versus control, Outcome 3 Any Adverse Events. ![An external file that holds a picture, illustration, etc. Object name is nCD004597-CMP-002-04.jpg](https://https://i0.wp.com/www.ncbi.nlm.nih.gov/pmc/articles/PMC6464930/bin/nCD004597-CMP-002-04.jpg) Analysis Comparison 2 Oral EPA versus control, Outcome 4 Performance status. ![An external file that holds a picture, illustration, etc. Object name is nCD004597-CMP-002-05.jpg](https://https://i0.wp.com/www.ncbi.nlm.nih.gov/pmc/articles/PMC6464930/bin/nCD004597-CMP-002-05.jpg) Analysis Comparison 2 Oral EPA versus control, Outcome 5 Quality of Life. ![An external file that holds a picture, illustration, etc. Object name is nCD004597-CMP-002-06.jpg](https://https://i0.wp.com/www.ncbi.nlm.nih.gov/pmc/articles/PMC6464930/bin/nCD004597-CMP-002-06.jpg) Analysis Comparison 2 Oral EPA versus control, Outcome 6 Total Calorific intake. Characteristics of studiesCharacteristics of included studies [ordered by study ID]MethodsRandomised double‐blind controlled parallel trialParticipantsN = 91 (E = 46 C = 45) Mixed Tumour CancerInterventionsE = Up to 18 capsules (1000 mg fish oil containing 180 mg EPA, 120 mg DSA) + 1 mg Vit E C = up to 18 capsules (1000 mg olive oil placebo)OutcomesAppetite, nausea, tiredness, well‐being, performance, anthropmetric measurements, weight gain, calorific intake, toleranceNotesJadad score 5 = 1+1+1+1+1Risk of biasBiasAuthors' judgementSupport for judgementAllocation concealment (selection bias)Low riskA ‐ Adequate MethodsRandomised double‐blind controlled parallel trialParticipantsN = 200 (E = 95, C = 105) Pancreatic cancer.InterventionsE = two cans nutritional supplement containing 32 g protein and 2.2 g EPA C = two cans nutritional supplement containing 32 g protein. Duration: eight weeksOutcomesBody weight gain kg/month LBM gain kg/month Survival/days Quality of life, Karnofsky scoresNotesJadad score 5 = 1+1+1+1+1Risk of biasBiasAuthors' judgementSupport for judgementAllocation concealment (selection bias)Low riskA ‐ Adequate MethodsRandomised controlled parallel trialParticipantsN = 60 E = 30 C1 = 30 Mixed tumoursInterventionsE = 18 g Fish oil (ea = 170 mg EPA, 115 DHA) + 200 mg Vit E C = placebo sugar tabletsOutcomesImmune status SurvivalNotesJadad score 2 = 1+0+0+1Risk of biasBiasAuthors' judgementSupport for judgementAllocation concealment (selection bias)High riskC ‐ Inadequate MethodsRandomised double‐blind controlled parallel trialParticipantsN = 421 E = 141 C1 = 140 C2 = 140InterventionsE = 2 cans EPA supplement 1.09 g + placebo C1 = MA liq susp 600 mg/d + placebo C2 = BothOutcomes‐ Body weight gain ‐ Quality of Life ‐ Appetite ‐ Survival ‐ ToleranceNotesJadad score 5 = 1+1+1+1+1Risk of biasBiasAuthors' judgementSupport for judgementAllocation concealment (selection bias)Low riskA ‐ Adequate MethodsRandomised double‐blind controlled parallel trialParticipantsN = 17 (E = 9, C = 8) Upper GI N = 4, Pancreatic N = 2, Rectal N = 1, Carcinoid = 1, Mesothelioma N = 1, Cervix N = 1, Oesophageal N = 1, Breast N = 2, Renal N = 1, NSC Lung = 2, Adenocarcinoma N = 1InterventionsE = 6 g EPA ethyl esters (96.8 % purity) C = 6 g oleic acid ethyl esters (79 % purity) Duration: seven daysOutcomesResting Energy Expediture Energy intake (kJ/d) Day 0, 2, 7)NotesJadad score 3 = 1+0+0+1+1Risk of biasBiasAuthors' judgementSupport for judgementAllocation concealment (selection bias)Unclear riskB ‐ Unclear Characteristics of excluded studies [ordered by study ID]StudyReason for exclusionParticipants not cancer patientsBefore and after trial Jadad score = 0+0+0Part of Barber's 2001 study Non‐randomised open labelled trial No control group Jadad score = 1 (0+0=1)Non‐randomised open labelled trial Jadad score = 1 (0+0+1)Non‐randomised open labelled trial Jadad score = 1 ( 0+0+1)Non‐randomised open labelled dose escalation trial No control group Jadad score = 1 (0+0=1)Non‐randomised open labelled trial No Control group Jadad score = 1 (0+0+1)Non randomised open labelled Before and After Trial No control group Jadad score = 1 (0+0+1)Non randomised open trial No control group Jadad score = 1 (0+0+1) Part of Fearon's 2001 studyPost operative administration of EPA supplementation Eligible for curative elective surgery only Excludes palliative cancer patientsPostoperative administration of EPA supplementation Eligible for curative elective surgery only Excludes palliative cancer patients/evidence of metastasisPreoperative administration of EPA supplementation Eligible for curative elective surgery only Excludes palliative cancer patientsPerioperative administration of EPA supplementation Eligible for curative elective surgery only Excludes palliative cancer patientsPreoperative administration of EPA supplementation Eligible for curative elective surgery onlyPerioperative and preoperative administration of EPA supplementation Excludes patients with equivalent or more than 10% weight lossReview of the studyPhase I dose response cohort study No control group Jadad score = 1 (0+0+1)Non‐randomised open trial No control group Jadad score = 1 (0+0+1)Postoperative administration of EPA supplementation Published outcomes: immune data, postoperative complications, length of stay in hospitalPre and Postoperative administration of EPA supplementation Not clear if curative or palliative Published outcomes: wound healing complications, infections, postoperative inpatient death, length of stay in hospitalRetrospective study on survival data from weight stabilisation Part of Fearon 2003 studyPostoperative administration of EPA supplementation Published outcomes: route of administration, postoperative complications, infectious complications, length of stay in hospitalNon‐randomised open trial No control group Jadad Score = 0 (0+0+0)Duplication of included study (Fearon 2003) multi‐centered trialPostoperative administration of EPA supplementation Eligible for curative elective surgery only Excludes palliative care Published outcomes: post‐operative infections and length of hospital stayPerioperative administration of EPA supplementation Excludes weight loss of equal to or more than 10 % with respect to usual body weight last six months Only two palliative cancer patients included (control) Published outcomes: post‐operative infections and length of hospital stayPreoperative administration of EPA supplementation Excludes weight equal to or more than 10 % with respect to usual body weight in past six months Published outcomes: post‐operative infections and length of hospital stayRetrospective Study; no controls Jadad Score = 0 (0+0+0)Post operative TPN (Total parenteral nutrition) of either Fish oil emulsion and soya oil versus soya oil aloneEarly Postoperative enteral feeding with EPA supplementation Published outcomes: postoperative complications, length of hospital stay, postoperative mortalityEarly Postoperative enteral feeding with EPA supplementation Published outcomes Immunological data onlyA Phase II Non‐randomised open trial (on‐going) No control group Jadad score = 1 (0+0+1)Preoperative administration of EPA supplementation 8/51 >10% weight loss Published outcomes: Immune function, infectious complicationsPoster presentation Sub‐analysis of included study () looking at 19 patients Outcomes: total energy expenditure and resting energy expenditurePoster presentation Sub‐analysis of included study (Fearon 2003) looking at 24 patients Outcomes: total energy expenditure and resting energy expenditureNo control or placebo arm Fish oil capsules (4.9 g of EPA, 3.2 g of DSA) versus melatonin 18 mg/day 1+0+1 = 2Part of Bruera 2003 study Published outcome measures: plasma and neutrophil fatty acid compositionOpen pilot study using 2 g EPA within a high protein concentrated supplement No randomisation, no blinding Description of dropouts given Jadad score = 0+0+1 = 1Randomised open trial No description of withdrawals/dropouts Only 7/30 cancer patients Jadad score = 0+0+0 = 0 Jadad Score =1(1+0++0)Postoperative administration of EPA supplementation Published outcomes: immune function, infectious complications, postoperative hospital stayPostoperative administration of EPA supplementation Published outcome: immune functionEarly postoperative feeding with EPA supplementation Published outcomes: reduced infections, wound complications, decreased treatment costsPerioperative Enteral administration of EPA supplementation Published outcomes: postoperative complications, length of hospital stay, decreased treatment costsPostoperative enteral feeding of EPA supplementation Published outcome: prostaglandin release from mononuclear cellsPre and postoperative administration of EPA supplementation Eligible for curative surgery cancer patients only Published outcomes: reduction of postoperative infections, wound healing complications, length of stay in hospitalOpen controlled trial no control group Published outcome: post‐operative immunity function only Jadad score = 0 (0+0+0)Open controlled trial postoperative Chemoradiation therapy No weight loss recorded No relevant clinical outcomes recorded (i.e., postoperative immunity function only) Jadad Score = 0 (0+0+0)Preoperative administration of EPA supplementation Published outcomes: immune and nutritional parameters evaluated No relevant clinical outcomesPoster presentation Sub‐analysis of included study (Fearon 2003) Outcomes: quality of life and grip strengthPreoperative administration of EPA supplementation Published outcomes; immune status, post‐operative infection No relevant clinical outcomesBefore and after study No control group Jadad score = 0 (0 = +0+0)Part of a Phase 1 Non‐randomised Trial No control group No relevant clinical outcomes In vitro and in vivo study looking at ability of EPA to down‐regulate the acute‐phase response Jadad score = 0 (0+0+0)Before and after trial Jadad score = 0 (0+0+0) Characteristics of ongoing studies [ordered by study ID]Trial name or titleA DBPCR Multi‐centre Phase Dose Response study of EPA 95% Diester Capsules in patients with cancer cachexiaMethods Participants243 lung & gastrointestinal patients to be recruited 81 patients in each of three groupsInterventionsOne group = 4 g EPA. Two groups = 2 g EPA Three groups = placebo Eight weeks durationOutcomesPrimary Ourcomes: Total body weight Secondary Outcomes Body composition Acute protein response Quality of Life Performance Status Plasma & Red cells phospholipidsStarting date1998Contact informationProfessor KC Fearon Depart of Clinical & Surgical Sciences, Royal Infirmary of Edinburgh, The Lothian University Hospitals NHS Trust, Lauriston Place, EDINBURGH EH3 9YWNotesTrial sponsored by Scotia Pharmaceutical Industry which subsequently went into liquidation Professor Fearon has obtained data and is currently analysing this data Contributions of authorsCB, TD, IJ, AD: conceived and designed review. AD: coordinated review. AD: developed search strategy, undertook searches/screened searches/organised retrieval of papers. AD, BH: screened retrieved papers against inclusion criteria. AD, BH, TD: appraised quality of papers. AD, BH: abstracted data from papers. AD: wrote to authors of papers for additional information. AD, TD, BH, CB, IJ: wrote up review. Sources of supportInternal sources
External sources
Declarations of interestNone known ReferencesReferences to studies included in this reviewBruera 2003 {published data only}
Fearon 2003 {published and unpublished data}
Gogos 1998 {published data only}
Jatoi 2004 {published data only}
Zuijdgeest 2000 {published data only}
References to studies excluded from this reviewAtkinson 1998 {published data only}
Barber 1998 {published data only}
Barber 1999a {published data only}
Barber 1999b {published data only}
Barber 2000 {published data only}
Barber 2001a {published data only}
Barber 2001b {published data only}
Barber 2004 {published data only}
Bauer 2005 {published data only}
Braga 1995 {published data only}
Braga 1996a {published data only}
Braga 1996b {published data only}
Braga 1999 {published data only}
Braga 2002 {published data only}
Braga 2002a {published data only}
Brosnahan 2003 {published data only}
Burns 1999 {published data only}
Burns 2004 {published data only}
Daly 1992 {published data only}
Daly 1995 {published data only}
Davidson 2004 {published data only}
Di Carlo 1999 {published data only}
Falconer 1994 {published data only}
Fearon 2001 {published data only}
Gianotti 1997 {published data only}
Gianotti 1999 {published data only}
Gianotti 2002 {published data only}
Gramaglia 1999 {published data only}
Heller 2004 {published data only}
Heslin 1997 {published data only}
Keman 1995 {published data only}
Mantovani 2004 {published data only}
McCarter 1998 {published data only}
Moses 2001 {published data only}
Moses 2002 {published data only}
Persson 2005 {published data only}
Pratt 2002 {published data only}
Read 2004 {published and unpublished data}
Rodrigo 1997 {published data only}
Schilling 1995 {published data only}
Senkal 1995 {published data only}
Senkal 1997 {published data only}
Senkal 1999 {published data only}
Swails 1997 {published data only}
Synderman 1999 {published data only}
Tashiro 1998a {published data only}
Tashirom 1998b {published data only}
Vignali 1995 {published data only}
vonMeyenfeldt 2002 {published data only}
Wachtler 1995 {published data only}
Wigmore 1996 {published data only}
Wigmore 1997 {published data only}
Wigmore 2000 {published data only}
References to ongoing studiesFearon 2005 {unpublished data only}
Additional referencesAltman 2001
Beck 1991
Belizario 1991
Blackburn 1977
Brodie 1998
DeWys 1980
Giacosa 1994
Hudson 1994
Jadad 1996
Jaskowiak 1998
Kyle 2004
Lindgvist 2004
Lindsey 1986
Nixon 1981
Ovesen 1993Ovesen L, Allingstrup L, Hannibal J, Mortensen EL, Hansen OP. Effect of dietary counselling on food intake, body weight, response rate, survival and quality of life in cancer patients undergoing chemotherapy: a prospective randomised study |